Últimas noticias sobre Molina Healthcare (NYSE:MOH) Bolsa

Molina Healthcare

Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.

Molina Healthcare Inc

MOTOR OIL HELLAS CORINTH by Motor Oil (Hellas) Corinth Refineries S.A.

Motor Oil (Hellas) Corinth Refineries SA

MOTOR OIL HELLAS UNSP/ADR by Motor Oil (Hellas) Corinth Refineries S.A.

Collaborative Investment Series Trust Mohr Growth ETF

Mohawk Industries Inc

Across the recent three months, 6 analysts have shared their insights on Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $371.17, with a high estimate of $406.00 and a low estimate of $331.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.76%. 
<img src="https://www.benzinga.com/files/images/story/2024/1734440483_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Molina Healthcare by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Stansel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$350.00</td>
<td>$378.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$362.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$372.00</td>
<td>$359.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$331.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Molina Healthcare. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Molina Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Molina Healthcare's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MOH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Molina Healthcare analyst ratings.</a>
<h2>Discovering Molina Healthcare: A Closer Look</h2>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Molina Healthcare's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 20.96% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 3.15%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Molina Healthcare's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.78% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Molina Healthcare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.11% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Molina Healthcare's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.53.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

The Analyst Verdict: Molina Healthcare In The Eyes Of 6 Experts

JP Morgan analyst John Stansel assumes Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Neutral rating and lowers Price Target of $350.

News

Price Target

Initiation

JP Morgan Assumes Molina Healthcare at Neutral, Lowers Price Target of $350

This new award follows the initial notice of intent to award the HIDE SNP contract announced by the MDHHS on October 9, 2024, and subsequently cancelled on November 8, 2024.&nbsp;
The go-live date for the new contract is expected to be January 1, 2026. The contract is expected to have a duration of seven years, with three one-year optional extensions.
 &nbsp;

Contracts

Molina Healthcare Bags Contract From Michigan Department Of Health And Human Services To Provide Dual Eligible Special Needs Plan; Also Secures Contract From Idaho Department Of Health And Welfare

Molina Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) short percent of float has fallen 24.26% since its last report. The company recently reported that it has 888 thousand shares sold short, which is 1.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Molina Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732197622_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Molina Healthcare has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Molina Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Molina Healthcare's peer group average for short interest as a percentage of float is 4.77%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Molina Healthcare's Recent Short Interest

WIIM

Shares of health insurance stocks are trading higher in possible reaction to President-elect Donald Trump indicating he plans to nominate Dr. Mehmet Oz as administrator for the Centers for Medicare and Medicaid Services. Oz has reportedly supported Medicare Advantage plans.

Michael Burry, the hedge fund manager renowned for predicting the 2008 financial crisis, has significantly increased his exposure to Chinese technology companies while simultaneously implementing protective measures against potential downside risks, <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">according to regulatory filings</a>.
What Happened: Burry&#8217;s Scion Asset Management made several notable adjustments to its portfolio during the third quarter, with Chinese companies now representing its largest positions. The firm increased its stake in Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) by 29%, making it the fund&#8217;s largest holding valued at over $21 million as of September&#8217;s end.
In a similar move, Scion doubled its position in JD.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), elevating it to the fund&#8217;s second-largest holding at approximately $20 million. The firm also expanded its stake in Chinese search giant Baidu Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) by 67%, bringing the position to $13.2 million.
However, in what appears to be a cautionary strategy, Burry has simultaneously established put options against these same holdings. Put options typically increase in value when the underlying securities decline, suggesting a hedging strategy designed to protect against potential market volatility.
See Also: <a href="https://www.benzinga.com/news/global/24/11/41999238/ross-gerber-blasts-teslas-support-for-ending-ev-tax-credit-as-insanity-amid-reported-policy-shift-under-trump-administration">Long-Time Tesla Bull Rages As Elon Musk Reportedly Backs Trump&#8217;s Plan To Ax $7.5K EV Credit: &#8216;Insanity&#8217;</a>
The timing of these moves coincides with Beijing&#8217;s recent economic stimulus announcements aimed at reinvigorating growth in the world&#8217;s second-largest economy. While Chinese equities initially rallied in September following these signals, gains have moderated as investors await more concrete fiscal measures.
Beyond his Chinese technology focus, Burry has also increased positions in several U.S. companies, including Shift4 Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>), American Coastal Insurance Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>), and Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>).
Why It Matters: Burry&#8217;s <a href="https://www.benzinga.com/markets/equities/24/10/41248334/big-short-investor-michael-burrys-china-bet-pays-off-as-top-picks-surge-nearly-60-in-2-months">top three Chinese holdings</a> have posted average gains of nearly 60% over a two-month period, according to market data.
Burry&#8217;s moves are being closely watched by market participants, particularly given his track record. He gained widespread recognition for his prescient bet against mortgage-backed securities before the 2008 global financial crisis, a story later chronicled in Michael Lewis&#8216;s bestseller &#8220;The Big Short&#8221; and its subsequent Oscar-winning film adaptation.
It&#8217;s worth noting that these positions reflect holdings as of Sep. 30, as required by SEC regulations for funds managing over $100 million in assets. Given the 45-day reporting delay and Burry&#8217;s active trading style, current positions may have already changed.
The development comes as other <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">prominent investors adjust their Chinese holdings</a>. Billionaire investor David Tepper&#8217;s Appaloosa Management recently reduced its Alibaba stake by 5%, though the position remains the fund&#8217;s largest holding at 15.75% of its $6.7 billion portfolio.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/content/41999311/jim-cramer-says-these-10-frothy-stocks-are-up-over-200-ytd-including-rocket-lab-palantir-and-carvana">Jim Cramer Says These 10 &#8216;Frothy&#8217; Stocks Are Up Over 200% YTD, Including Rocket Lab, Palantir, And Carvana</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Global

Markets

ACIC

BABA

BIDU

FOUR

'Big Short' Investor Michael Burry Doubles Down On Chinese Tech Stocks While Adding Protective Hedges

OLPX

Scion Asset Management 13F Shows Increased Stake In Alibaba Group From 155,000 To 200,000 Shares; Increased Stake In JD.com From 250,000 To 500,000 Shares;  Increased Stake In Shift4 Payments From 100,000 To 150,000 Shares; Increased Stake In Baidu From 75,000 To 125,000 Shares; Increased Stake In Molina Healthcare From 24,530 To 30,000 Shares; Increased Stake In Olaplex Holdings From 995,250 To 1,000,000 Shares

On Wednesday, Donald Trump, the Republican candidate and former president, was elected to the highest office again, marking a return to an administration. His second term is likely to impact U.S. healthcare.
Trump has been unclear about his healthcare policy goals during his campaign. Healthcare <a target="_blank" href="https://www.kff.org/health-care-in-2024-elections-apvotecast-polling/?entry=kff-analysis-of-ap-votecast-abortion-ballot-initiatives" rel="noreferrer noopener">ranked</a> lower than issues like the economy and immigration in voter concerns.
A <a target="_blank" href="https://apnews.com/article/ap-votecast-elections-harris-trump-voters-d5cf4e3611f50ec4349d93ddc7f037cd" rel="noreferrer noopener">poll</a> from the Associated Press found that only 8% of voters viewed healthcare as their top issue, compared to 39% who chose the economy and 20% who picked immigration. Abortion was the leading issue for 11% of voters.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction" rel="noreferrer noopener">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a>
Despite his focus on &#8220;Make America Healthy Again,&#8221; millions of Americans may lose health insurance subsidies next year, depending on the political climate after the election and the Republicans&#8217; control of the Senate.
The subsidies, expanded under the 2021 American Rescue Plan, help many, particularly the middle class, afford health insurance through the Affordable Care Act (ACA).
These subsidies are set to expire at the end of 2025, and it remains uncertain whether they will be extended under the new administration.
Trump and other Republicans have opposed continuing the subsidies.
The NBC News <a target="_blank" href="https://www.nbcnews.com/health/health-news/millions-risk-losing-health-insurance-trumps-victory-rcna179146" rel="noreferrer noopener">report</a>, citing some analysts, suggests that the chances of extension could be less than 5% if Republicans win control of the House and the Senate.
Even if Democrats control the House, extending these subsidies seems unlikely. Without an extension, nearly 4 million Americans could lose coverage by 2026 due to unaffordable premiums.
The 2021 changes led to a surge in ACA enrollment, with 15.5 million people benefiting from subsidies across 32 states. The report adds that if the subsidies aren&#8217;t renewed, up to 15.4 million Americans could lose health coverage by 2030.
Another significant issue is Trump&#8217;s stance on Medicare. As president, he supported Medicare Advantage, a private insurer-run program that could eventually replace traditional, government-run Medicare.
The NPR report <a target="_blank" href="https://www.npr.org/sections/shots-health-news/2024/11/07/nx-s1-5183092/trump-election-2024-medicare-advantage" rel="noreferrer noopener">highlights</a> that critics argue that expanding private insurers could increase costs for taxpayers and limit care, with some beneficiaries finding it difficult to switch back to traditional Medicare.
Robert Berenson, a former government official, warned that traditional Medicare could &#8220;wither on the vine.&#8221;
Medicare Advantage grew with the 2003 legislation introducing a drug benefit and expanded private insurers&#8217; role in the program. Although private plans were expected to lower costs, they have been more expensive.
The report also says that in 2023, Medicare Advantage plans cost taxpayers about 6% — or $27 billion — more than traditional Medicare, though some research suggests they offer better care.
The future of healthcare policy in the U.S. will depend on the political dynamics in Congress and Trump&#8217;s second term.
With Republicans pushing for major changes to the ACA and Medicare, experts warn of significant shifts in how Americans access and pay for healthcare in the coming years.
Read Next
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41855578/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap-but-novo-nordisk-and-lilly-suffer-market-setbacks" target="_blank" rel="noreferrer noopener">Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks</a></li>
</ul>
Photo via Shutterstock

Government

Regulations

Health Care

Politics

General

ALHC

CLOV

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Laboratory Corporation Of America Holdings

Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare

Wells Fargo analyst Stephen Baxter maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Equal-Weight and raises the price target from $360 to $362.

Wells Fargo Maintains Equal-Weight on Molina Healthcare, Raises Price Target to $362

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 20 years by 4.8% on an annualized basis producing an average annual return of 13.16%. Currently, Molina Healthcare has a market capitalization of $18.13 billion. 
Buying $100 In MOH: If an investor had bought $100 of MOH stock 20 years ago, it would be worth $1,261.31 today based on a price of $317.01 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730136615_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Molina Healthcare 20 Years Ago Would Be Worth This Much Today

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares jumped 21.97% following the earnings<a href="https://www.benzinga.com//node/41537560" target="_blank" rel="noreferrer noopener"> beat and overall market strength</a>.</li>
<li>Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) shares increased 14.02% last week. The People's Bank of China <a href="https://www.benzinga.com//node/41547149" target="_blank" rel="noreferrer noopener">injected 700 billion yuan</a> ($98.36 billion) into the banking system through its one-year medium-term lending facility, keeping the rate steady at 2.0%.</li>
<li>Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) stock surged 12.36% after the company<a href="https://www.benzinga.com//node/41500855" target="_blank" rel="noreferrer noopener"> reported third-quarter results</a>.</li>
<li>Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) shares gained 11.83% following a report alleging that a <a href="https://www.benzinga.com//node/41550527" target="_blank" rel="noreferrer noopener">judge blocked the company's proposed acquisition</a> of Capri Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>). The company said it intends to appeal the decision.</li>
<li>Applovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) gained 11.30% last week after several analysts <a href="https://www.benzinga.com/quote/APP/analyst-ratings" target="_blank" rel="noreferrer noopener">raised their price forecasts</a> on the stock.</li>
<li>Booz Allen Hamilton Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) shares gained 10.99% after reporting better-than-expected Q2 financial results and <a href="https://www.benzinga.com//node/41543105" target="_blank" rel="noreferrer noopener">strong FY25 guidance</a>.</li>
<li>Digital Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) shares upped 9.45% after reporting better-than-expected Q3 FFO results and raising FY24 FFO guidance. Several analysts <a href="https://www.benzinga.com/quote/DLR/analyst-ratings" target="_blank" rel="noreferrer noopener">raised their price forecasts</a> on the stock.</li>
<li>Grab Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) stock gained 9.12% last week. Daiwa Capital initiated coverage on the stock with an Outperform rating and <a href="https://www.benzinga.com/quote/GRAB/analyst-ratings" target="_blank" rel="noreferrer noopener">a $4.60 price target</a>.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares were up <a href="https://www.benzinga.com//node/41544385" target="_blank" rel="noreferrer noopener">8.56% amid a rise in Bitcoin</a>.</li>
<li>Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) shares upped 8.03% after the company reported better-than-expected third-quarter results and several <a href="https://www.benzinga.com//node/41499153" target="_blank" rel="noreferrer noopener">analysts raised the price target</a>.</li>
</ol>
Photo via Shutterstock

Large Cap

Movers

CPRI

GRAB

MSTR

TSLA

Tesla, Li Auto And MicroStrategy Are Among Top 10 Large Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?

Barclays analyst Andrew Mok maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Equal-Weight and raises the price target from $359 to $372.

Barclays Maintains Equal-Weight on Molina Healthcare, Raises Price Target to $372

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining over 100 points on Thursday.
The Dow traded down 0.42% to 42,337.45 while the NASDAQ rose 0.65% to 18,396.30. The S&amp;P 500 also rose, gaining, 0.15% to 5,806.21.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41512422/top-3-tech-stocks-youll-regret-missing-in-q4">Top 3 Tech Stocks You&#8217;ll Regret Missing In Q4</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 3.2% on Thursday.
In trading on Thursday, materials shares fell by 1.4%.
Top Headline
Dow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) reported better-than-expected third-quarter results.
Sales rose 1% year over year to $10.88 billion, beating the consensus of $10.65 billion, on higher sales in the U.S. and Canada. Adjusted EPS was $0.47, beating the consensus of $0.46.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Nxu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) shares shot up 116% to $0.5406. Nxu and Verde Bioresins reported a proposed merger.</li>
<li>Shares of QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) got a boost, surging 24% to $6.43 after the company said it has begun producing low volumes of its first B-sample cells and has begun shipping cells for automotive customer testing.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) shares were also up, gaining 20% to $330.40 after the company reported better-than-expected third-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Beyond, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) shares dropped 33% to $6.39 after the company reported worse-than-expected third-quarter adjusted EPS and sales.</li>
<li>Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) were down 82% to $0.3019 after the company announced its Phase 3 TrustTSC trial of Oral Ganaxolone did not meet its primary endpoint.</li>
<li>Community Health Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) was down, falling 23% to $4.29 following third-quarter earnings.</li>
</ul>
Commodities In commodity news, oil traded down 1% to $70.08 while gold traded up 0.7% at $2,748.60.
Silver traded down 0.1% to $33.825 on Thursday, while copper rose 0.6% to $4.3605.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.03%, Germany's DAX gained 0.34% and France's CAC 40 rose 0.08%. Spain's IBEX 35 Index fell 0.21%, while London's FTSE 100 rose 0.13%.
The S&amp;P Global UK composite PMI declined to 51.7 in October from 52.6 in September, while Eurozone composite edged higher rose to 49.7 in October versus 49.6 in the previous month.
The HCOB Germany composite PMI increased to 48.4 in October versus 47.5 in September, while French composite PMI slipped to 47.3 in October from 48.6 in September.
Asia Pacific Markets
Asian markets closed mostly lower on Thursday, with Japan's Nikkei 225 gaining 0.10%, Hong Kong's Hang Seng Index falling 1.30%, China's Shanghai Composite Index falling 0.68% and India's BSE Sensex falling 0.02%.
The HSBC India composite PMI rose to 58.6 in October from 58.3 in the prior month. The au Jibun Bank Flash Japan composite PMI declined to 49.4 in October compared to a final reading of 52.0 in September.
Economics
<ul>
<li>The Chicago Fed National Activity Index fell to a reading of -0.28 in September compared to a revised level of -0.01 in August.</li>
<li>U.S. initial jobless claims declined by 15,000 from the prior week to 227,000 during the period ending Oct. 19, compared to market estimates of 242,000.</li>
<li>U.S. building permits declined by 3.1% to an annual rate of 1.425 million in September.</li>
<li>The S&amp;P Global flash manufacturing PMI rose to 47.8 in October versus a 15-month low level of 47.3 in September.</li>
<li>The S&amp;P Global services PMI increased to 55.3 in October from 55.2 in the prior month.</li>
<li>Sales of new single-family homes in the U.S. surged 4.1% to an annual rate of 738,000 in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41516316/jim-cramer-says-he-would-not-buy-this-health-care-stock-at-this-level-wait-for-a-pullbac">Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: &#8216;Wait For A Pullback&#8217;</a></li>
</ul>

BYON

MRNS

Crude Oil Down 1%; Dow Posts Upbeat Earnings

Cantor Fitzgerald analyst Sarah James reiterates Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Overweight and maintains $406 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Molina Healthcare, Maintains $406 Price Target

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.3% on Thursday.
The Dow traded down 0.72% to 42,206.88 while the NASDAQ rose 0.26% to 18,323.75. The S&amp;P 500 also fell, dropping, 0.16% to 5,788.23.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41512422/top-3-tech-stocks-youll-regret-missing-in-q4">Top 3 Tech Stocks You&#8217;ll Regret Missing In Q4</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 2.6% on Thursday.
In trading on Thursday, materials shares fell by 1.1%.
Top Headline
Shares of Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) fell around 4% on Thursday after the company reported third-quarter results and updated FY24 guidance.
Revenue grew 6% year-over-year (organic: +3%) to $9.728 billion, missing the consensus of $9.901 billion. Adjusted EPS was $2.58 (+8% Y/Y), beating the consensus of $2.50.
For FY24, the company lowered sales guidance to $38.6 billion – $38.8 billion (from $39.1 billion – $39.7 billion prior) versus the consensus of $39.20 billion. Honeywell tightened adjusted EPS guidance to $10.15 – $10.25 (from $10.05 – $10.25) versus the estimate of $10.13.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Nxu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) shares shot up 216% to $0.7930. Nxu and Verde Bioresins reported a proposed merger.</li>
<li>Shares of QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) got a boost, surging 25% to $6.49 after the company said it has begun producing low volumes of its first B-sample cells and has begun shipping cells for automotive customer testing.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) shares were also up, gaining 22% to $336.39 after the company reported better-than-expected third-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Beyond, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) shares dropped 26% to $7.03 after the company reported worse-than-expected third-quarter adjusted EPS and sales.</li>
<li>Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) were down 80% to $0.3413 after the company announced its Phase 3 TrustTSC trial of Oral Ganaxolone did not meet its primary endpoint.</li>
<li>Community Health Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) was down, falling 23% to $4.2550 following third-quarter earnings.</li>
</ul>
Commodities In commodity news, oil traded down 0.7% to $70.29 while gold traded up 0.4% at $2,741.10.
Silver traded down 0.1% to $33.790 on Thursday, while copper fell 0.1% to $4.3350.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.25%, Germany's DAX gained 0.54% and France's CAC 40 rose 0.27%. Spain's IBEX 35 Index rose 0.12%, while London's FTSE 100 rose 0.28%.
The S&amp;P Global UK composite PMI declined to 51.7 in October from 52.6 in September, while Eurozone composite edged higher rose to 49.7 in October versus 49.6 in the previous month.
The HCOB Germany composite PMI increased to 48.4 in October versus 47.5 in September, while French composite PMI slipped to 47.3 in October from 48.6 in September.
Asia Pacific Markets
Asian markets closed mostly lower on Thursday, with Japan's Nikkei 225 gaining 0.10%, Hong Kong's Hang Seng Index falling 1.30%, China's Shanghai Composite Index falling 0.68% and India's BSE Sensex falling 0.02%.
The HSBC India composite PMI rose to 58.6 in October from 58.3 in the prior month. The au Jibun Bank Flash Japan composite PMI declined to 49.4 in October compared to a final reading of 52.0 in September.
Economics
<ul>
<li>The Chicago Fed National Activity Index fell to a reading of -0.28 in September compared to a revised level of -0.01 in August.</li>
<li>U.S. initial jobless claims declined by 15,000 from the prior week to 227,000 during the period ending Oct. 19, compared to market estimates of 242,000.</li>
<li>U.S. building permits declined by 3.1% to an annual rate of 1.425 million in September.</li>
<li>The S&amp;P Global flash manufacturing PMI rose to 47.8 in October versus a 15-month low level of 47.3 in September.</li>
<li>The S&amp;P Global services PMI increased to 55.3 in October from 55.2 in the prior month.</li>
<li>Sales of new single-family homes in the U.S. surged 4.1% to an annual rate of 738,000 in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41516316/jim-cramer-says-he-would-not-buy-this-health-care-stock-at-this-level-wait-for-a-pullbac">Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: &#8216;Wait For A Pullback&#8217;</a></li>
</ul>

Earnings

Eurozone

Commodities

Nasdaq Edges Higher; Honeywell Shares Fall After Q3 Results

U.S. stocks were mixed, with the Nasdaq Composite gaining around 100 points on Thursday.
Shares of United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) rose during Thursday's session after the company reported <a href="https://www.benzinga.com/news/earnings/24/10/41515619/delivery-giant-ups-breaks-revenue-miss-streak-after-10-quarters-stock-soars">better-than-expected quarterly EPS and sales.</a>
UPS reported consolidated revenue growth of 5.6% year-over-year to $22.2 billion, beating the consensus of $22.14 billion. Adjusted EPS was $1.76, up 12.1% YoY, above the consensus of $1.63.
United Parcel Service shares jumped 5% to $137.93 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) shares jumped 31.6% to $6.82 after the company said it has begun producing low volumes of its first B-sample cells and has begun shipping cells for automotive customer testing.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) gained 22.8% to $337.89 after the company reported better-than-expected third-quarter financial results.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) climbed 20.7% to $345.82 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance above estimates. Also, the company increased its fourth-quarter dividend.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) gained 18.7% to $71.65 after the company reported better-than-expected third-quarter EPS results.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) gained 17.7% to $14.67 after the company reported better-than-expected third-quarter financial results.</li>
<li>American Coastal Insurance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) surged 16.8% to $12.09 after the company provided updates on hurricane loss amounts and announced it expects a positive net income for the third quarter.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 16.5% to $248.93 following better-than-expected quarterly earnings.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) climbed 15.6% to $66.48 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 15.2% to $33.33 after the company presented data from its ongoing Phase 1a/1b study of ZL-1310 for previously treated extensive-stage small cell lung cancer at the EORTC-NCI-AACR Symposium 2024.</li>
<li>Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) gained 14.2% to $79.66.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) surged 13.2% to $29.72 after the company announced it bagged a contract with the Space Development Agency as the prime contractor to the US Government.</li>
<li>ADT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>) gained 11.2% to $7.70 after the company reported better-than-expected third-quarter financial results and issued FY24 adjusted EPS above estimates.</li>
<li>Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) rose 10% to $109.18 following a third-quarter EPS beat and guidance above consensus estimates.</li>
<li>Plexus Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) rose 9.9% to $149.00 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 9.9% to $12.00 after Keybanc maintained an Overweight rating on the stock and raised its price target from $11 to $12.</li>
<li>CBRE Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NASDAQ">CBRE</a>) gained 9.7% to $135.12 after the company reported better-than-expected third-quarter financial results and raised its FY24 adjusted EPS guidance above estimates.</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) rose 8.2% to $629.72 following upbeat quarterly earnings.</li>
<li>Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) gained 7.6% to $236.52 following strong quarterly earnings.</li>
<li>Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) gained 7.5% to $377.11 following strong quarterly sales.</li>
<li>T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) gained 4.1% to $230.00 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41516316/jim-cramer-says-he-would-not-buy-this-health-care-stock-at-this-level-wait-for-a-pullbac">Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: &#8216;Wait For A Pullback&#8217;</a></li>
</ul>

Intraday Update

ASTS

CBRE

PEGA

PLXS

POOL

RKLB

TMUS

VKTX

ZLAB

UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $377.14, a high estimate of $406.00, and a low estimate of $331.00. Observing a downward trend, the current average is 0.11% lower than the prior average price target of $377.57. 
<img src="https://www.benzinga.com/files/images/story/2024/1729771211_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Molina Healthcare's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$331.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$360.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$353.00</td>
<td>$354.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$378.00</td>
<td>$351.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Molina Healthcare. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Molina Healthcare compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Molina Healthcare's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Molina Healthcare's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MOH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Molina Healthcare analyst ratings.</a>
<h2>About Molina Healthcare</h2>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Molina Healthcare displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 18.65%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 3.05%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Molina Healthcare's ROE stands out, surpassing industry averages. With an impressive ROE of 6.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Molina Healthcare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.96% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.49.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Molina Healthcare: Insights From 7 Financial Analysts

Molina Healthcare shares are trading higher after the company reported better-than-expected Q3 financial results.

Baird analyst Michael Ha maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Outperform and lowers the price target from $405 to $331.

Baird Maintains Outperform on Molina Healthcare, Lowers Price Target to $331

As police hunt for the shooter who killed UnitedHealthcare's CEO Brian Thompson, UnitedHealth (UNH) is simultaneously trying to cope with the perso...

CEO killing, rage over insurance pushes UnitedHealth into crisis, Bloomberg says

Jefferies lowered the firm's price target on Elevance Health (ELV) to $458 from $529 and keeps a Buy rating on the shares. After "extensive analysi...

Elevance Health price target lowered to $458 from $529 at Jefferies

Jefferies analyst David Windley lowered the firm's price target on Molina Healthcare (MOH) to $312 from $348 and keeps a Hold rating on the shares....

Molina Healthcare price target lowered to $312 from $348 at Jefferies

Worst performing stocks for tax loss selling – Wolfe

Molina Healthcare (MOH) announced that the Michigan Department of Health and Human Services has awarded a contract to Molina's health plan subsidia...

Molina Healthcare awarded new contracts in Michigan, Idaho

Molina Healthcare ( ($MOH) ) has issued an announcement. Molina Healthcare has been awarded a contract by the Michigan Department of Health and Hum...

Molina Healthcare Expands with New State Contracts

JPMorgan analyst John Stansel downgraded Molina Healthcare (MOH) to Neutral from Overweight with a price target of $350, down from $378, after assu...

Molina Healthcare assumed with Neutral from Overweight at JPMorgan

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Tesla upgraded, MongoDB initiated: Wall Street's top analyst calls

IHF: Healthcare Dashboard For December

U.S. healthcare spending climbs 7.5% in 2023

ACHC

ACLS

AGCO

ALGM

AMKR

APLS

ATKR

BIIB

BMRN

BRBR

CLVT

CNMD

CNXC

COLD

COLL

COMM

CTSH

DINO

DXCM

ENPH

EPAM

FIVN

FLNC

GEHC

GLOB

HNST

HRMY

INTC

IONS

IPGP

LNTH

MCHP

MRNA

MTCH

NEOG

OPCH

OSCR

OTEX

PTEN

QDEL

QRVO

RBRK

REGN

REXR

SEDG

SGRY

SLAB

STNE

SWKS

SYNA

VEEV

WOLF

XRAY

Press Releases

Molina Healthcare Reports Second Quarter 2024 Financial Results

Molina Healthcare Signs CEO Joe Zubretsky to New Employment Agreement

Molina Healthcare Senior Executive Vice President and CFO Mark Keim to Expand Role to Include Leadership of the Medicaid Health Plans and Marketplace Business

Molina Healthcare Announces Third Quarter 2024 Earnings Release and Conference Call Dates and Investor Day Meeting

Molina Healthcare Wins Michigan Contract to Provide a New Dual Eligible Benefit Program

Molina Healthcare Reports Third Quarter 2024 Financial Results

Molina Healthcare Announces Proposed Offering of $500 Million of Senior Notes Due 2033

Molina Healthcare Announces Pricing of $750 Million of 6.250% Senior Notes Due 2033

Molina Healthcare Announces Closing of Offering of $750 Million of 6.250% Senior Notes Due 2033

Molina Healthcare Awarded Contracts to Serve Dual Eligible Populations in Michigan and Idaho

Comments

Molina Healthcare

Noticias

Últimas noticias sobre Molina Healthcare (NYSE:MOH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL